Schizophrenia

Featured Article
Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Mark Munger, PharmD, explains why careful observation of patients being treated with ACEi based on salt classification may be warranted in patients with active symptoms or with a family history of schizophrenia.
Added Pimavanserin Shows Positive Trends in Schizophrenia but Misses Primary Endpoint in Trial
“Unfortunately, we did not achieve a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score in this study,” said Acadia Pharmaceuticals president Serge…
Jury Still Out on Best Oral Antipsychotic for Multi-Episode Schizophrenia
Most oral antipsychotics are effective for acute treatment of multi-episode schizophrenia in adults, but it's not clear which, if any, is best, according to a new network meta-analysis comparing 32…

Newsfeed

Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Added Pimavanserin Shows Positive Trends in Schizophrenia but Misses Primary Endpoint in Trial
Jury Still Out on Best Oral Antipsychotic for Multi-Episode Schizophrenia
Cognitive Decline Continues After Onset of Psychosis
Smoking Normalizes Dynamic Brain Activity in Schizophrenia
Schizophrenia, Antipsychotic Use Associated With ECG Changes
Tailored Program Might Help Some With Severe Mental Illness Quit Smoking
Certain Types of Antipsychotic Polypharmacy Feasible in Schizophrenia Treatment
View More

Insights

Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Mark Munger, PharmD, explains why careful observation of patients being treated with ACEi based on salt classification may be warranted in patients with active symptoms or with a family history of schizophrenia.
Schizophrenia Therapy: Do Cost-Saving Strategies Conflict With Care?
Formulary decisions for treating schizophrenia must balance saving costs and improving medication  adherence without contributing to the disease burden.
Managing Mental Health: Tackling Schizophrenia Head On
Managing Mental Health is a 3-part series dedicated to exploring the challenges managed care professionals face regarding the treatment of mental health illnesses, with a specific focus on dementia, schizophrenia, and depression.
New Versus Old Injectable Antipsychotics for Schizophrenia
Long-acting injectable (LAI) antipsychotics are highly effective in the management of schizophrenia and associated with a number of potential advantages over oral antipsychotics. First-generation LAIs (LA1s) have been available for more than 50…
View More
Back to Top